Zotepine

Zotepine

Clinical data
Trade names	Zoleptil
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	N05AX11 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	7-13% (Oral)
Metabolism	N-desmethylation to norzotepine (30-40%)
Biological half-life	13.7-15.9 hours, 12 hours (Norzotepine)
Excretion	17% (Urine)
Identifiers
IUPAC name 2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethylethanamine
CAS Number	26615-21-4 N
PubChem CID	5736
IUPHAR/BPS	103
DrugBank	DB09225 N
ChemSpider	5534 Y
UNII	U29O83JAZW
KEGG	D01321 Y
ChEBI	CHEBI:32316 Y
ChEMBL	CHEMBL285802 Y
ECHA InfoCard	100.189.143
Chemical and physical data
Formula	C18H18ClNOS
Molar mass	331.86
3D model (Jmol)	Interactive image
SMILES Clc2cc1C(/OCCN(C)C)=C\c3c(Sc1cc2)cccc3
InChI InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3 Y Key:HDOZVRUNCMBHFH-UHFFFAOYSA-N Y
NY (what is this?)

Zotepine (brand names: Losizopilon (JP), Lodopin (ID, JP), Setous (JP), Zoleptil (CZ, PT, TR, UK†); where † indicates a formulation that has been discontinued) is an atypical antipsychotic drug indicated for acute and chronic schizophrenia. It has been used in Germany since 1990 (although it has been discontinued in Germany) and Japan since 1982.

Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.

Zotepine's primary use is as a treatment for schizophrenia although clinical trials have been conducted (with positive results) into its efficacy as an antimanic agent in patients with acute bipolar mania.

The antipsychotic effect of zotepine is thought to be mediated through antagonist activity at dopamine and serotonin receptors. Zotepine has a high affinity for the D₁ and D₂ receptors. It also affects the 5-HT_2A, 5-HT_2C, 5-HT₆, and 5-HT₇ receptors. In addition, its active metabolite, norzotepine, serves as a potent norepinephrine reuptake inhibitor.